SpeeDx Pty, Ltd. a developer of innovative molecular diagnostic solutions announced an investment in SynGenis Pty Ltd., an experienced oligonucleotide manufacturer based in Western Australia. The partnership will bolster the internal capacity of SpeeDx to support large-scale increases in manufacturing while developing and expanding the sovereign capacity of important raw materials used in molecular diagnostics.

In addition to securing a local supply chain to strengthen sovereign capacity for critical diagnostics and a more robust national health infrastructure, SpeeDx investment in the local industry serves to fast track the growth and reach of SynGenis in the global diagnostics market.

“We have invested considerable resources into our production scale-up processes to support the increase in testing seen as a result of the global pandemic,” said Tom Lin, SpeeDx Director of Global Operations. “Enhancing our access to quality raw materials ensures we remain committed to maintaining supply chain security for our customers worldwide.”

The increased demand for Covid-19 diagnostics has in turn increased global demand for the oligonucleotide raw materials that form the basis of molecular diagnostic products. In addition to this supply chain burden, reduced flights and increased customs challenges entering Australia has complicated freight and delivery times from overseas suppliers. SpeeDx investment in local oligonucleotide manufacturing reduces supply chain risk and develops a stronger sovereign capacity for critical diagnostics for a more robust national health infrastructure.